The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/ajp.119.5.465

From the data obtained from the present sample, the following conclusions may be drawn: 1) considering the rigorously controlled setting in which the drug was evaluated, Ensidon seems to be an adequately potent antidepressant substance reaching the statistical significance beyond 0.05 level; 2) the indication par excellence is that Ensidon seems to be effective in neurotic depressive states clinically and statistically and there is a relative lack of side effects and the sedative properties of this drug adds further to its suitability for ambulatory patients.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.